This excerpt taken from the ABII 8-K filed Nov 8, 2007.
Use of Cash Contribution
As described further in Strategy above, we intend to use the approximately $715 million to be contributed to us in connection with the separation and related transactions primarily to establish our presence globally in connection with the worldwide commercialization of Abraxane®, to support clinical trial activity to expand indications for Abraxane®, to invest in research and development to commercialize our clinical and discovery pipelines and for potential strategic opportunities as well as for general corporate purposes, including working capital and capital expenditures. We currently anticipate that we will spend at least $250 million in the aggregate for 2008 and 2009 in support of clinical studies to expand the indications for Abraxane® and continued development of our product pipeline. We also currently anticipate that we will spend at least $60 million in the aggregate for 2008 and 2009 to establish our European infrastructure for the commercialization of Abraxane® across Europe. As of the date of this information statement, we have not specifically allocated the remaining funds for the other categories. We believe the approximately $715 million to be contributed to us, together with our anticipated cash generated from operations, will be sufficient to finance our operations for at least the next twelve months and to fund our anticipated Phase III trials for our current clinical product candidates. However, product development efforts may not result in commercial products and the amount and timing of our research and development expenses may change due to many factors, including the introduction of competitive products or unanticipated clinical trial results. The amount and timing of our actual expenditures will depend upon numerous factors, including the requirements of our product development and commercialization efforts, the need for capacity expansion and improvement and the amount of cash generated by our operations. Pending any specific use of the approximately $715 million contributed to us, we generally intend to invest these funds in short-term, investment grade, interest-bearing securities.